Causal association between local infection of Epstein-Barr virus and gastric cancer risk: a rapid meta-analysis [0.03%]
爱泼斯坦-巴尔病毒局部感染与胃癌发病风险因果关联的快速荟萃分析
Zhuo-Yu Li,Rui Wang,Xin-Zu Chen;SIGES Research Group
Zhuo-Yu Li
The potential of (177Lu)-PSMA-617 in the first-line combination therapy with enzalutamide for metastatic castration-resistant prostate cancer: clinical insights from the ENZA-p trial [0.03%]
恩杂鲁胺临床试验(ENZA-P)的临床启示：在转移性去势抵抗性前列腺癌的一线联合治疗中，PSMA-617的潜力
Renning Zheng,Stephen J Freedland,Anthony T Nguyen
Renning Zheng
Paclitaxel and carboplatin combination therapy-induced pure red cell aplasia in endometrial cancer patient and favorable response to low-dose corticosteroid treatment: a case report [0.03%]
紫杉醇联合卡铂治疗子宫内膜癌诱发纯红细胞再生障碍性贫血及小剂量激素治疗的病例报道
Chengyulong Zheng,Meng Chen,Jiayu He et al.
Chengyulong Zheng et al.
Background: Endometrial cancer, the sixth most common malignancy in women, is frequently treated with carboplatin-paclitaxel chemotherapy. While myelosuppression is a common adverse effect, drug-induced pure red cell apla...
Case Reports
Chinese clinical oncology. 2025 Oct;14(5):58. DOI:10.21037/cco-25-32 2025
Induction chemotherapy followed by radiotherapy in primary small cell neuroendocrine carcinoma of the parotid gland: a case report and literature review [0.03%]
腮腺原发小细胞神经内分泌癌化疗联合放疗的临床效果及1例报告
Ruoyu Deng,Lin Wang,Jialing Lv et al.
Ruoyu Deng et al.
Background: Small cell carcinoma is a highly aggressive neoplasm that commonly arises in the lungs. The occurrence of this tumor in the salivary gland, particularly the parotid gland, is extremely rare, accounting for les...
Case Reports
Chinese clinical oncology. 2025 Oct;14(5):57. DOI:10.21037/cco-24-129 2025
Natural compounds targeting mitochondrial metabolism in cancer therapy: a literature review [0.03%]
癌症治疗中针对代谢途径的天然化合物的研究进展综述
Grazielle Silva Paz,Janaina Fernandes
Grazielle Silva Paz
Background and objective: Cancer is a public health problem and is considered the leading cause of death around the globe. Despite the advances in cancer therapies, many patients suffer from adverse side effects and drug ...
Neoadjuvant chemoimmunotherapy or chemoradiotherapy in stage III non-small cell lung cancer: crossing the Rubicon? [0.03%]
III期非小细胞肺癌的新辅助化疗免疫治疗或化学放射治疗：跨过Rubicon河？
Juan Carlos Redondo-González,Luis Posado-Domínguez,Laura Corvo-Félix et al.
Juan Carlos Redondo-González et al.
Background and objective: Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) represents 80-85% of cases, with 20-35% diagnos...
The global impact of the General Data Protection Regulation: implications, challenges, and future outlook in oncology clinical research sponsors [0.03%]
欧盟通用数据保护条例对肿瘤临床研究发起者的全球影响：涵义、挑战及未来前景展望
Xiao Liu,Denis Lacombe,Stephane Lejeune
Xiao Liu
Oncology clinical trial involves processing of vast amounts of personal health data, including medical history, treatment, biomarker, genetic information, etc., much of which qualifies as special category data under the General Data Protect...
Afatinib for patients with non-small-cell lung cancer harboring major EGFR G719X + S768I co-mutations: a retrospective, observation study in Xuanwei and Fuyuan, China [0.03%]
阿法替尼治疗中国宣威和富源地区EGFR G719X+S768I复合突变非小细胞肺癌患者：一项回顾性观察研究
Ruoyu Deng,Lin Wang,Jialing Lv et al.
Ruoyu Deng et al.
Background: Real-world data on afatinib for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) G719X + S768I co-mutations remains limited. This study aims to evaluate the ef...